BIOMAT Database Logo BIOMAT Database Logo

Efficacy and tolerability of erythromycin acistrate and erythromycin stearate in acute skin infections of patients with atopic eczema. 1988

O P Salo, and A Gordin, and H Brandt, and R Antikainen
Department of Allergic Diseases, Helsinki University Central Hospital, Finland.

The efficacy and tolerability of a new erythromycin derivative, erythromycin acistrate (EA), were compared with that of erythromycin stearate (ES) in 42 patients with infected atopic eczema. The dosage of EA was 400 mg tid and that of ES 500 mg tid. The duration of treatment ranged from five to 12 days. The patients were hospitalized and evaluated before treatment and on the last day in hospital. The infective pathogen was usually Staphylococcus aureus in both groups. Without local antibacterial treatment both drugs eradicated the bacteria in more than 60% of the cases. Gastrointestinal side effects were frequently reported with both drugs, more often in the ES- than in the EA-group, but the difference was only statistically significant (p less than 0.05) with respect to diarrhoea. One patient in each group discontinued treatment because of gastrointestinal side effects. No elevations in liver enzymes of clinical significance were reported in either group.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009824 Ointments Semisolid preparations used topically for protective emollient effects or as a vehicle for local administration of medications. Ointment bases are various mixtures of fats, waxes, animal and plant oils and solid and liquid hydrocarbons. Ointment,Paste,Pastes,Salve,Unguent,Salves,Skin Ointment,Unguents,Ointment, Skin
D011355 Prodrugs A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. Drug Precursor,Drug Precursors,Pro-Drug,Prodrug,Pro-Drugs,Precursor, Drug,Precursors, Drug,Pro Drug,Pro Drugs
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D003876 Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema. Eczema, Atopic,Eczema, Infantile,Neurodermatitis, Atopic,Neurodermatitis, Disseminated,Atopic Dermatitis,Atopic Eczema,Atopic Neurodermatitis,Disseminated Neurodermatitis,Infantile Eczema
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004917 Erythromycin A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erycette,Erymax,Erythromycin A,Erythromycin C,Erythromycin Lactate,Erythromycin Phosphate,Ilotycin,T-Stat,Lactate, Erythromycin,Phosphate, Erythromycin,T Stat,TStat
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

O P Salo, and A Gordin, and H Brandt, and R Antikainen
Efficacy of erythromycin acistrate (2'-acetyl erythromycin stearate) and erythromycin stearate in experimental infections in mice.
September 1989, The Journal of pharmacology and experimental therapeutics,
O P Salo, and A Gordin, and H Brandt, and R Antikainen
Effect of erythromycin acistrate and erythromycin stearate on human colonic microflora.
January 1989, Scandinavian journal of infectious diseases,
O P Salo, and A Gordin, and H Brandt, and R Antikainen
Erythromycin acistrate and erythromycin stearate in the treatment of non-gonococcal urethritis.
June 1988, The Journal of antimicrobial chemotherapy,
O P Salo, and A Gordin, and H Brandt, and R Antikainen
Comparison of erythromycin acistrate and enterocoated erythromycin base in acute respiratory infections.
June 1988, The Journal of antimicrobial chemotherapy,
O P Salo, and A Gordin, and H Brandt, and R Antikainen
Hepatic safety of erythromycin acistrate in 1549 patients with respiratory tract or skin infections.
February 1991, The Journal of antimicrobial chemotherapy,
O P Salo, and A Gordin, and H Brandt, and R Antikainen
Erythromycin acistrate and enterocoated pellets of erythromycin base in acute respiratory infections of hospitalized conscripts.
June 1988, The Journal of antimicrobial chemotherapy,
O P Salo, and A Gordin, and H Brandt, and R Antikainen
Penetration of erythromycin into periapical lesions after repeated doses of erythromycin acistrate and erythromycin stearate: a pilot study.
June 1991, Oral surgery, oral medicine, and oral pathology,
O P Salo, and A Gordin, and H Brandt, and R Antikainen
Treatment of respiratory tract infections with erythromycin acistrate and two formulations of erythromycin base.
June 1988, The Journal of antimicrobial chemotherapy,
O P Salo, and A Gordin, and H Brandt, and R Antikainen
Efficacy and tolerance of roxithromycin in comparison with erythromycin stearate in patients with lower respiratory tract infections.
January 1992, Scandinavian journal of infectious diseases,
O P Salo, and A Gordin, and H Brandt, and R Antikainen
Concentrations of erythromycin, 2'-acetyl erythromycin, and their anhydro forms in plasma and tonsillar tissue after repeated dosage of erythromycin stearate and erythromycin acistrate.
July 1988, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!